Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary-Reference-Cited by-同舟云学术

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary

Published:2017-12 Issue:12 Volume:13 Page:832-837
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Hanna Nasser¹,Johnson David¹,Temin Sarah¹,Masters Gregory¹

Affiliation:

1. Indiana University Simon Cancer Center, Indianapolis, IN; University of Texas Southwestern Medical Center, Dallas, TX; American Society of Clinical Oncology, Alexandria, VA; Helen F. Graham Cancer Center and Research Institute, Newark, DE

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2017.026716

Reference22 articles.

1. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

3. Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PARP1 actives cGAS-STING signaling pathway to promote tumor cells apoptosis and reshape tumor immune microenvironment in non-small cell lung cancer;2023-10-13

2. Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC;JTO Clinical and Research Reports;2023-05

3. Prognostic influence of PD-1/PD-L1 suppressors in combination with chemotherapeutic agents for non-small cell pulmonary carcinoma: system review and meta-analysis;Frontiers in Oncology;2023-04-19

4. Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer;ESMO Open;2023-04

5. Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment;Frontiers in Health Services;2023-03-13